Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 4, 2015
Pharmacy Choice - Pharmaceutical News - Reports on Allergan's Continued Work on Hair Loss Product Despite Delays - October 4, 2015

Pharmacy News Article

 3/7/14 - Reports on Allergan's Continued Work on Hair Loss Product Despite Delays

(PRWEB) March 07, 2014

Allergan's move to take part in the massive hair loss market is the subject of the latest report. The current lineup of Allergan products include JUV?DERM, BOTOX, VIVITE, SkinMedica, NATRELLE breast implants and LATISSE. It is this last product that was the launching point for Allergan's attempt to enter the hair loss market reports The active ingredient, bimatoprost was found to improve eyelash growth, and Allergan researchers are hoping it can do the same for hair.

The report also discusses the size of market itself and the opportunity that it poses for Allergan to increase its revenue by hundreds of millions of dollars. A hair loss product would open up an entirely new demographic for Allergan that includes millions of men in the U.S. alone. reports that early estimates suggest Allergan could generate upwards of $500 million a year by 2020 if they were able to get a hair loss product approved by the FDA.

Allergan started the FDA approval process with a first phase trial study in 2010. Despite not having FDA approval yet, reports that some doctors have already been using LATISSE off-label to treat male pattern baldness in patients that have allergic reactions to minoxidil-based products. Though Allergan's bimatoprost hair loss product has shown promise, Allergan made the decision last year to put the third and final FDA trial phase on hold.

Given the disappointment with Allergan's decision to put the bimatoprost hair loss product on hold it's no surprise that the company still plans to move forward with research. David Pyott, Allergan's Chief Executive, assured investors that the company would do more studies on the hair loss product before conducting late-stage FDA trials. Earlier this year Allergan announced they would be boosting research spending to $1 billion, which is an indicator that the company is still invested in creating a new hair loss product even though FDA trials have stalled.

To learn more about LATISSE products or to see the full report on Allergan's move into the hair loss market, please visit:

About was created to provide a faster, less expensive and more convenient way to purchase authentic LATISSE products. is able to accomplish this by having patients fill in a medical history form which a registered physician will review. This allows customers to purchase LATISSE online without visiting a physician, saving customers time and money. is a subsidiary of Allied Medical & Diagnostic Services, LLC.

Read the full story at

(c) 2014 PRWEB.COM Newswire

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Oct 05: Using Effective Communication to Reduce Medication Errors
Last Chance
Oct 06: Medication Disposal: Implications for Pharmacies
Oct 07: Efficacy vs. Safety: Treating BPH & Incontinence in the Elderly
Oct 12: Comprehensive Asthma Care: Opportunities for Pharmacy Professionals
Oct 13: Florida Medication Error Reduction
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement